Literature DB >> 16735169

Control of onchocerciasis.

Boakye A Boatin1, Frank O Richards.   

Abstract

Onchocerciasis is a filarial infection which causes blindness and debilitating skin lesions. The disease occurs in 37 countries, of which 30 are found in Africa (the most affected in terms of the distribution and the severity of the clinical manifestations of the disease), six in the Americas and one in the Arabian Peninsula. The latest WHO Expert Committee on Onchocerciasis estimated that in 1995 around 17.7 million persons were infected, about 270,000 of whom were blind and another 500,000 severely visually impaired. The disease is responsible for 1 million DALYs. Eye disease from onchocerciasis accounts for 40% of DALYs annually although severe skin disease is also recognized as of public health significance. Great progress has been made in the last thirty years in the control of onchocerciasis, both in Africa and the Americas, and this progress has been due largely to international public-private partnerships, sustained funding regional programmes, and new tools and technology. Landmarks in the global control of river blindness include the significant success of the Onchocerciasis Control Programme of West Africa (1975-2002), and the donation of ivermectin (Mectizan) by Merck & Co. Inc., in 1988, a medicine that is distributed to millions free of charge each year. Future major technical challenges of onchocerciasis control include ivermectin mass administration in areas co-endemic for the parasite Loa loa in the light of possible severe adverse reactions, ivermectin treatment in hypoendemic areas hitherto excluded from African control programmes, sustainability of ivermectin distribution, post-control surveillance for recrudescence detection, surveillance for emergence of resistance, and decisions of when to stop mass ivermectin treatments. There is the need to develop the appropriate information systems and diagnostic tools to help in accomplishing many of these tasks. A search for a second-line treatment or as an additional drug to ivermectin as well as a search for a macrofilaricide are issues that need to be addressed in the future.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16735169     DOI: 10.1016/S0065-308X(05)61009-3

Source DB:  PubMed          Journal:  Adv Parasitol        ISSN: 0065-308X            Impact factor:   3.870


  64 in total

1.  Preventive chemotherapy in human helminthiasis: theoretical and operational aspects.

Authors:  A-F Gabrielli; A Montresor; L Chitsulo; D Engels; L Savioli
Journal:  Trans R Soc Trop Med Hyg       Date:  2011-10-29       Impact factor: 2.184

Review 2.  Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis.

Authors:  Ayokunle T Abegunde; Richard M Ahuja; Nkem J Okafor
Journal:  Cochrane Database Syst Rev       Date:  2016-01-15

Review 3.  Onchocerciasis: the role of Wolbachia bacterial endosymbionts in parasite biology, disease pathogenesis, and treatment.

Authors:  Francesca Tamarozzi; Alice Halliday; Katrin Gentil; Achim Hoerauf; Eric Pearlman; Mark J Taylor
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

4.  Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model.

Authors:  Jessica A Hess; Bin Zhan; Sandra Bonne-Année; Jessica M Deckman; Maria Elena Bottazzi; Peter J Hotez; Thomas R Klei; Sara Lustigman; David Abraham
Journal:  Int J Parasitol       Date:  2014-06-05       Impact factor: 3.981

5.  Efficacy of 5-week doxycycline treatment on adult Onchocerca volvulus.

Authors:  Achim Hoerauf; Sabine Specht; Yeboah Marfo-Debrekyei; Marcelle Büttner; Alexander Yaw Debrah; Sabine Mand; Linda Batsa; Norbert Brattig; Peter Konadu; Claudio Bandi; Rolf Fimmers; Ohene Adjei; Dietrich W Büttner
Journal:  Parasitol Res       Date:  2008-10-11       Impact factor: 2.289

Review 6.  Epidemiology of plasmodium-helminth co-infection in Africa: populations at risk, potential impact on anemia, and prospects for combining control.

Authors:  Simon Brooker; Willis Akhwale; Rachel Pullan; Benson Estambale; Siân E Clarke; Robert W Snow; Peter J Hotez
Journal:  Am J Trop Med Hyg       Date:  2007-12       Impact factor: 2.345

7.  Cost and cost-effectiveness of nationwide school-based helminth control in Uganda: intra-country variation and effects of scaling-up.

Authors:  Simon Brooker; Narcis B Kabatereine; Fiona Fleming; Nancy Devlin
Journal:  Health Policy Plan       Date:  2007-11-17       Impact factor: 3.344

8.  Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study.

Authors:  Achim Hoerauf; Sabine Specht; Marcelle Büttner; Kenneth Pfarr; Sabine Mand; Rolf Fimmers; Yeboah Marfo-Debrekyei; Peter Konadu; Alexander Yaw Debrah; Claudio Bandi; Norbert Brattig; Anna Albers; John Larbi; Linda Batsa; Mark J Taylor; Ohene Adjei; Dietrich W Büttner
Journal:  Med Microbiol Immunol       Date:  2007-11-13       Impact factor: 3.402

9.  Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden.

Authors:  Peter J Hotez; Aruna Kamath
Journal:  PLoS Negl Trop Dis       Date:  2009-08-25

10.  Advancing drug innovation for neglected diseases-criteria for lead progression.

Authors:  Solomon Nwaka; Bernadette Ramirez; Reto Brun; Louis Maes; Frank Douglas; Robert Ridley
Journal:  PLoS Negl Trop Dis       Date:  2009-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.